✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
SHR3824 is an investigational drug.
There have been 15 clinical trials for SHR3824. The most recent clinical trial was a Phase 1 trial, which was initiated on June 1st 2017.
The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Liver Diseases. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Shandong Suncadia Medicine Co., Ltd., and [disabled in preview].
There are three US patents protecting this investigational drug and thirty-five international patents.
Recent Clinical Trials for SHR3824
|A Study to Assess the Bioequivalence of Fixed Dose Combination of HR20033 Relative to Co-administration of the Individual Components in Healthy Chinese Subjects||Shandong Suncadia Medicine Co., Ltd.||Phase 1|
|A Study to Assess the Effect of Food on HR20033 and Pharmacokinetic After Multiple Dose in Healthy Volunteers||Shandong Suncadia Medicine Co., Ltd.||Phase 1|
|Drug-drug Interaction Between Simvastatin and SHR3824||Jiangsu HengRui Medicine Co., Ltd.||Phase 1|
Top disease conditions for SHR3824
Top clinical trial sponsors for SHR3824
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|SHR3824||See Plans and Pricing||L-proline complex of sodium-glucose cotransporter 2 inhibitor, monohydrate and crystal form thereof||Jiangsu Hengrui Medicine Co., Ltd. (Lianyungang, Jiangsu, CN)||See Plans and Pricing|
|SHR3824||See Plans and Pricing||Compounds as peptidic GLP1/glucagon/GIP receptor agonists||SANOFI (Paris, FR)||See Plans and Pricing|
|SHR3824||See Plans and Pricing||Compounds as peptidic trigonal GLP1/glucagon/GIP receptor agonists||SANOFI (Paris, FR)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|SHR3824||Brazil||BR112017005454||2034-09-30||See Plans and Pricing|
|SHR3824||Canada||CA2961819||2034-09-30||See Plans and Pricing|
|SHR3824||China||CN105992769||2034-09-30||See Plans and Pricing|
|SHR3824||European Patent Office||EP3202772||2034-09-30||See Plans and Pricing|
|SHR3824||Spain||ES2836099||2034-09-30||See Plans and Pricing|
|SHR3824||Hungary||HUE052588||2034-09-30||See Plans and Pricing|
|SHR3824||Japan||JP2017530107||2034-09-30||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|